Japan probes Biomet-Zimmer merger

September 10, 2014 by Brad Perriello

Japanese regulators are the latest to probe the pending merger of Biomet and Zimmer to make sure it meets anti-trust muster.

Japanese anti-trust regulators are the latest to scrutinize the pending merger of Zimmer (NYSE:ZMH) and Biomet, joining agencies in the U.S. and Europe that are already looking at the deal.

The Japan Fair Trade Commission said Sept. 3 that it’s opening an investigation into the $13.35 billion mega-deal between the orthopedic device giants, 1st announced in April.

“With the knowledge that a more in-depth review is necessary, today, the JFTC requested Zimmer, etc. to submit further reports, information or materials,” the Japanese agency said in a press release. “The JFTC also starts seeking comments from 3rd parties concerning possible impacts on competition that would arise through the proposed integration.”



Josh Sandberg

Josh Sandberg is the President of Ortho Sales Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *